Avoro Capital Advisors LLC

Q3 2026 13F-HR Holdings

Location
New York, NY
Holdings as of
9/30/2026
Date filed
11/16/2026
Form type
13F-HR
Num holdings
30
Total value ($000)
$9,690,900
Net value change ($000)
-1,445,350 (-13.0%)
New positions
5
Sold out positions
1
Turnover %
3.5%
Sector allocation + QoQ delta (equities-only)

Snapshot: Change Analysis

Compared to Q2 2026
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
DAMORA THERAPEUTICS INC 80,502 NEW
ABVX 48,322 NEW
SCRIBE THERAPEUTICS INC 47,834 NEW
BIOHAVEN LTD 36,713 NEW
ARGX 31,140 3.4%
BRAVEHEART BIO INC 25,351 NEW
RVMD 10,101 2.3%
SEPN 6,076 13.6%
SNSE 5,832 16.2%
VRDN 5,550 12.1%
Top Reduces (Value $000, Stocks/ETFs)
CELC -236,428 -66.5%
Ascendis Pharma AS -212,694 -15.6%
ARWR -205,641 -22.2%
QURE -147,338 -47.5%
GPCR -146,845 -41.7%
XENE -144,202 -41.3%
KRYS -112,984 -10.5%
CYTK -102,991 -24.2%
GLTO -98,396 -100.0%
DFTX -69,842 -20.7%
Instrument mix + QoQ Δ (ex-options)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type